•HBM Healthcare Investments, Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs join existing investors Frazier Healthcare Partners, Bain Capital Life Sciences, OrbiMed and RA Capital Management
•Funds Phase 3 clinical development of lead product candidate ARQ-151 topical cream in plaque psoriasis
•Also funds continued development of ARQ-151 in atopic dermatitis WESTLAKE VILLAGE, Calif., October 21, 2019-- Arcutis Biotherapeutics, Inc. ("Arcutis"), a privately held clinical-stage biopharmaceutical company focusing on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has completed a $94.5 million Series C financing led by HBM Healthcare Investments.